Gilead (NASDAQ:GILD) just released data for a new hepatitis C combination therapy, and the results are staggering: a 100% cure rate! The news sent the stock soaring more than 13% on Monday. In this video, Motley Fool health care analyst Brenton Flynn breaks down the market potential for Gilead's new therapy and talks about another company with similarly excellent results that will want a share of that market for itself.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.